Application for Clinical Guideline Assessment by Fluorescent Measurements of Sensitizer Molecule in Tumor

Abstract

Quantitative data of the fluorescence intensity accumulated in clinical malignant brain tumor tissues (astrocytoma) were obtained from a good number of photodynamic diagnosis (PDD)-operated samples in this study. From where, it has been resulted that the concentration/intensity increases exponentially with the increase in the grades of the astrocytoma. It was found that the ratio values (I_635nm/I_500nm) of the fluorescence intensity against the green autofluorescence one follows the similar exponential increment for the more sensitive cancer grades with the changes on fluorescence intensity. Finally, it reflected that the ratio values could be very much helpful to estimate the Pp-IX concentration from the obtained calibration curve, as a follow through it could be a very important tool to estimate the dose of photodynamic therapy (PDT) and thereby the treatment efficiency of cancer, especially for the cases where different fluorescence concentration is estimated due to different cancer grades in a single tissue. Thus, this technique can be added as a measure of new dose calculation similar to that of the boron neutron capture therapy (BNCT), which is a new presentation for the clinical laser PDT guideline. It was also elucidated that the fluoresced metabolized material was a precursor of Hem namely, protoporphyrin-IX (Pp-IX), because the measurement by a mass spectroscopic analysis and then the comparison of the microscopic image of the mass spectroscopy with the fluorescent one matched completely through overlapping of both images.